TrialThe AAPS journal2015

Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9.

Nageshwar R Budha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.